Press Release: New Phase IIIB data shows Novartis -2-

References

1. Novartis. Data on file.

2. Clinicaltrials.gov. NCT05630001. Single Arm, Open Label Trial With

Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of

Anti-C5 Who Switch to Iptacopan. (APPULSE). Available from:

https://clinicaltrials.gov/study/NCT05630001 Accessed October, 2024.

3. McKinley CE, Richards SJ, Munir T, et al. Extravascular Hemolysis Due to

C3-Loading in Patients with PNH Treated with Eculizumab: Defining the

Clinical Syndrome. Blood. 2017;130(Supplement 1):3471.

4. Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients

with paroxysmal nocturnal hemoglobinuria receiving treatment with the

C5-inhibitors eculizumab or ravulizumab: results from a US patient

survey. Ann Hematol. 2022;101(2):251-263.

5. Levy AR, Dysart L, Patel Y, et al. Comparison of Lost Productivity Due to

Eculizumab and Ravulizumab Treatments for Paroxysmal Nocturnal

Hemoglobinuria in France, Germany, Italy, Russia, Spain, the United

Kingdom, and the United States. Blood. 2019;134(Supplement_1):4803.

6. Fabhalta(R). US FDA Prescribing information. East Hanover, NJ:Novartis

Pharmaceuticals Corp; 2024. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218276s001lbl.pdf Accessed

November 2024.

7. Fabhalta(R). EMA Summary of Product Characteristics. Novartis Europharm

Limited; 2024. Available from:

https://www.ema.europa.eu/en/documents/product-information/fabhalta-epar-product-information_en.pdf Accessed

November 2024.

8. Fabhalta(R). PMDA Drug Information Sheet. Novartis Pharma KK; 2024.

Available from: https://www.pmda.go.jp/files/000271929.pdf Accessed

November 2024.

9. Fabhalta(R). NMPA drug insert. Novartis Pharma Schweiz AG; 2024.

Available from:

https://www.ccfdie.org/en/gzdt/webinfo/2024/05/1716632195327630.html

Accessed November 2024.

10. Dighriri IM, Al-Qahtani RM, Almutairi AO, et al. Iptacopan Efficacy and

Safety to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic

Review and Meta-Analysis. Cureus. 2024;16(8):e67830.

11. Novartis. Press release. Novartis receives FDA accelerated approval for

Fabhalta(R) (iptacopan), the first and only complement inhibitor for the

reduction of proteinuria in primary IgA nephropathy (IgAN). Available

from:

https://www.novartis.com/news/media-releases/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan Accessed

October, 2024.

12. Risitano AM, Araten DJ, Kuter D, et al. Pb2063: APPULSE-PNH: A phase IIIB

trial to evaluate the efficacy and safety of switching to iptacopan in

patients with paroxysmal nocturnal hemoglobinuria (PNH) on anti-c5

therapy with hemoglobin >10g/dl. Hemasphere. 2023;7(Suppl):e08587b7.

13. Cançado RD, Araújo ADS, Sandes AF, et al. Consensus statement

for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria.

Hematol Transfus Cell Ther. 2021;43(3):341-348.

14. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal

haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028.

15. Röth A, Maciejewski J, Nishimura JI, Jain D, Weitz JI. Screening and

diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria:

Expert consensus. Eur J Haematol. 2018;101(1):3-11.

16. Risitano AM, Marotta S, Ricci P, et al. Anti-complement Treatment for

Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement

Inhibition? A Position Paper From the SAAWP of the EBMT. Front Immunol.

2019;10:1157.

17. Shammo et al. HemaSphere 2023 Shammo J, Kim J, Georget M, et al. P796:

Hospitalization in patients with paroxysmal nocturnal hemoglobinuria: a

retrospective analysis of observational study data from the United

States. Hemasphere. 2023;7(Suppl):e22585a2.

18. Debureaux PE, Kulasekararaj AG, Cacace F, et al. Categorizing

hematological response to eculizumab in paroxysmal nocturnal

hemoglobinuria: a multicenter real-life study. Bone Marrow Transplant.

2021;56(10):2600-2602.

19. Schrezenmeier H, Kulasekararaj A, Mitchell L, et al. One-year efficacy

and safety of ravulizumab in adults with paroxysmal nocturnal

hemoglobinuria naïve to complement inhibitor therapy: open-label

extension of a randomized study. Ther Adv Hematol.

2020;11:2040620720966137.

20. Young NS, Meyers G, Schrezenmeier H, Hillmen P, Hill A. The management of

paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and

treatment and new hope for patients. Semin Hematol. 2009;46(1 Suppl

1):S1-S16.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line:

+41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Isabella Zinck +41 61 324 7188 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Jonathan Graham +1 201 602 9921

Imke Kappes +41 61 324 8269 Parag Mahanti +1 973 876 4912

(END) Dow Jones Newswires

December 06, 2024 01:15 ET (06:15 GMT)